Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward

Table 2

Ongoing trials in the adjuvant therapy setting for gastric cancer.

Trial	Phase/patients sample	Tumor; location	Intervention	Primary endpoint
ARTIST II; (NCT00407186)	III; 1,000	Stomach/GEJ	A: Surgery→S-1 + RT/S-1 + CDDP + RT; B: S-1/S-1 + CDDP	DFS
CRITICS; (NCT00407186)	III; 788	Stomach/GEJ	A: ECC/EOC→Surgery→CC + RT; B: ECC/EOC→Surgery→ECC/EOC	OS
TOPGEAR	II/III; 752	Stomach/GEJ	A: FU/C + RT→Surgery→ECF/EOX; B: ECF/EOX→Surgery→ECF/EOX	OS
MAGIC-B; (NCT00450203)	II/III; 1,100	Stomach/GEJ	A: ECX + BEV→Surgery→ECX + BEV; B: ECX + BEV→Surgery→ECX + BEV	OS
JCOG; (NCT00252161)	III; 316	Stomach/GEJ	A: S-1 + CDDP→Surgery→S-1; B: Surgery→S-1	OS
RTOG-1010; (NCT01196390)	III; 480	Middle-lower esophageal/GEJ	A: C-PAC + RT + H→Surgery→H; B: C-PAC + RT→Surgery	DFS
NCT01711242	III; 300	Stomach	A: Surgery→XELOX; B: Surgery→XELOX/RT/XELOX	DFS
TOXAG; (NCT01748773)	II; 40	Stomach/GEJ	Surgery→XELOX + H + RT	Safety/tolerability

RT: radiation therapy, 45 Gy.
S-1: tegafur/gimeracil/oteracil.
CDDP: cisplatin.
ECC: epirubicin/cisplatin/capecitabine.
EOC: epirubicin/oxaliplatin/capecitabine.
FU: 5-fluorouracil.
ECF: epirubicin/cisplatin/5-fluorouracil.
ECX: epirubicin/cisplatin/capecitabine.
BEV: bevacizumab.
C: carboplatin.
PAC: paclitaxel.
H: trastuzumab.
XELOX: oxaliplatin-capecitabine.